Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment

Cardiology

Volumn 113, Issue 4, 2009, Pages 277-286

  Nigmatullina, Razina R ^a   Kirillova, Venera V ^a   Jourjikiya, Roen K ^a   Mukhamedyarov, Marat A ^a   Kudrin, Vladimir S ^b   Klodt, Petr M ^b   Palotás, András ^c,d  

^a KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^c Asklepios Med Bt Private Practice and Research Center   (Hungary)

^d Asklepios Med Bt   (Hungary)

Author keywords

3,4 dihydroxy L phenyl alanine; 5 hydroxy indole acetic acid; Catecholamines; Chronic heart failure, biomarkers; Diastolic dysfunction; Dopamine; Left ventricular hypertrophy; Serotonin; Systolic dysfunction

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 5 HYDROXYINDOLEACETIC ACID; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPA; DOPAMINE; KETANSERIN; NORADRENALIN; SARPOGRELATE; SEROTONIN; SEROTONIN 2 AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CATECHOLAMINE BLOOD LEVEL; CHRONIC DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; ELECTROCHEMICAL DETECTION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESTENOSIS; SEROTONINERGIC SYSTEM; SYSTOLIC DYSFUNCTION; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADRENAL GLANDS; ADRENERGIC BETA-ANTAGONISTS; ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; DOPAMINE; EPINEPHRINE; FEMALE; HEART FAILURE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; NOREPINEPHRINE; SEROTONIN; SEVERITY OF ILLNESS INDEX; SYMPATHETIC NERVOUS SYSTEM;

EID: 61449157818     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205962     Document Type: Article

References (35)

1. Esler M, Kaye D:Measurement of sympathetic nervous system activity in heart failure:the role of norepinephrine kinetics. Heart Fail Rev 2000;5:17-25 .
2. Garg R, Yusuf S, Collaborative Group on ACE-Inhibitor Trials:Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;271:1450-1456.
3. Cote F, Fligny C, Fromes Y:Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004;10:232-238.
4. Vikenes K, Farstad M, Nordrehaug JE:Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999;100:483-489.
5. Cooper JR, Bloom FE, Roth RH:The Biochemical Basis of Neuropharmacology, ed 8. New York, Oxford University Press, 2002, pp 271-320.
6. Vanhoutte PM:Platelet-derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991;17(suppl 5):S6-S12.
7. Trip MD, Volkert MC, Van Capelle FJL, Vreeken J:Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-1554.
8. Pakala R, Willerson JT, Benedict CR:Effect of serotonin, thromboxane A2, and specific antagonists on vascular smooth muscle cell proliferation. Circulation 1997;96:2280-2286.
9. Serruys PW, Klein W, Tijssen JPG, Rutsch W, Heyndrickx GR, Emanuelsson H, Ball SG, Decoster O, Schroeder E, Liberman H, Eichorn E, Willerson JT, Anderson HV, Khaja F, Alexander RW, Baim D, Melkert R, Van Oene JC, Van Gool R:Evaluation of ketan-serin in the prevention of restenosis after percutaneous transluminal coronary angioplasty:a multicenter randomized double-blind placebo-controlled trial. Circulation 1993;88:1588-1601.
10. Prichard BN, Smith CC:Serotonin:receptors and antagonists - summary of symposium. Clin Physiol Biochem 1990;8(suppl 3):120-128.
11. Jaffre F, Callebert J, Sarre A, Etienne N, Nebigil C, Launay JM, Maroteaux L, Monassier L:Involvement of the serotonin 5-HT 2b receptor in cardiac hypertrophy linked to sympathetic stimulation:control of interleukin-6, interleukin-1β, and tumor necrosis factor-α cytokine production by ventricular fibroblasts. Circulation 2004;110:969-974.
12. Kirillova VV, Jordjikiya RK, Nigmatullina RR:Adrenergic and serotoninergic regulation of myocardium from patients with different morphofunctional alterations of heart in chronic heart failure. Bull Exp Biol Med 2007;144:830-833.
13. Gillis CN, Pitt BR:The fate of circulating amines within the pulmonary circulation. Annu Rev Physiol 1982;44:269-281.
14. Sauer WH, Berlin JA, Kimmel SE:Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003;108:32-36.
15. Weyman AE:Principles and Practice of Echocardiography, ed 2. Philadelphia, Lea &Febiger, 1994.
16. Mustafin AA, Nigmatullina RR, Mirolubov LM, Kalinicheva YB, Kudrin VS, Klodt PM:The role of serotoninergic system in development of lung arterial hypertension in children with congenital heart disease. Klinicheskaya Fiziologiya Krovoobrascheniya 2007;2:42-46.
17. Paez X, Hernandez I:Plasma serotonin monitoring by blood microdialysis coupled to high-performance liquid chromatography with electrochemical detection in humans. J Chromatogr B 1998;720:33-38.
18. Kronik G, Slany J, Mosslacher H:Comparative value of eight M-mode echocardio-graphic formulas for determining left ventricular stroke volume. Circulation 1979;60:1308-1316.
19. Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB:New index of combined systolic and diastolic myocardial performance:a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy. J Cardiol 1995;26:357-366.
20. Schiller NB, Shah PM, Crawford M, De-Maria A, Devereux R , Feigenbau m H, Gutgesell H, Reichek N, Sahn D, Schnittger I:Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echo-cardiograms. J Am Soc Echocardiogr 1989;2:358-367.
21. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB:Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:1636-1644.
22. Rakowski H, Appleton C, Chan KL, Du-mesnil JG, Honos G, Jue J, Koilpillai C, Lepage S, Martin RP, Mercier LA, O'Kelly B, Prieur T, Sanfilippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C, Tomlinson C:Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography:from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996;9:736-760.
23. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB:Left atrial volume:important risk marker of incident atrial fibrillation in 1,655 older men and women. Mayo Clin Proc 2001;76:467-475.
24. Otto CM:The Practice of Clinical Echocardiography, ed 2. Philadelphia, WB Saunders, 2002.
25. Yamachika S, Reid CL, Savani D, Meckel C, Paynter J, Knoll M, Jamison B, Gardin JM:Usefulness of color Doppler proximal isove-locity surface area in quantitating valvular regurgitation. J Am Soc Echocardiogr 1997;10:159-168.
26. Lee RJ, Bartzokis T, Yeoh TK, Grogin HR, Choi D, Schnitther I:Enhanced detection of intracardiac sources of cerebral emboli by transthoracic echocardiography. Stroke 1991;22:734-739.
27. Ashton JH, Ogletree M, Michel IM, Golino P, McNatt JM, Taylor AL, Raheja S, Schmitz J, Buja LM, Campbell WB, Willerson JT:Cooperative mediation by serotonin S2 and tromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987;76:952-959.
28. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M, Chiariello M:Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-648.
29. Noble MIM, Drake-Holland AJ:Evidence for a role of serotonin in inhibition of coronary arterial thrombosis in dog and man. Clin Physiol Biochem 1991;8(suppl 3):50 -55.
30. Boor PJ, Hysmith RM, Sanduja R:A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res 1990;66:249-252.
31. Ni W, Watts SW:5-hydroxytryptamine in the cardiovascular system:focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006;33:575-583.
32. Serebruany VL, O'Connor CM, Gurbel PA:Effect of selective serotonin reuptake inhibitors on platelets i n patients with corona r y artery disease. Am J Cardiol 2001;87:1398-1400.
33. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
34. Francis GS, Benedict CR, Johnstone DE, Kirlin P, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S;for SOLVD (studies of left ventricular dysfunction) investigators:Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990;82:1724-1729.
35. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP:Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990;322:1561-1566.